Biomea Fusion (BMEA) risk factors, FY2024 10-K

Other

1. 01Risks Related to Our Limited Operating History, Business, Financial Condition, Results of Operations, and Need for Additional Capital
2. 02We have a limited operating history, limited experience in conducting clinical trials, have not completed any clinical trials, have no products approved for commercial sale, and have not generated any revenue, which may make it difficult for you to evaluate our current business and likelihood of success and viability
3. 03We have limited experience as a company in conducting clinical trials and have not successfully completed the clinical development of any product candidates to date. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history
4. 04We have incurred significant net losses in each period since our inception, and we expect to incur significant net losses for the foreseeable future
5. 05operate as a public company
6. 06We have not generated any revenue from our product candidates and may never generate revenue or be profitable. Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery and development of our product candidates
7. 07attracting, hiring, and retaining qualified personnel
8. 08We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and product development programs or future commercialization efforts
9. 09the impact of adverse global economic conditions on our business, which may exacerbate the magnitude of the factors discussed above
10. 10There is substantial doubt about our ability to continue as a going concern
11. 11Based on our current operating plan, we will not be able to continue as a going concern over the next twelve months unless we raise additional capital by other means. These factors raise substantial doubt about our ability to continue as a going concern
12. 12to grow our business, pursue acquisitions or improve our operating infrastructure and restrict our ability to compete in our markets
13. 13respond to competitive pressures
14. 14Potential or actual breach of financial covenants in any credit agreements or credit arrangements

Risks Related to Product Development

1. 15such product candidates will subsequently demonstrate significant clinical benefit in vivo or in larger trials or will be well-tolerated
2. 16Our novel approach to the discovery and development of our current and future product candidates is unproven, and we may not be successful in our efforts to use and expand our FUSIONTM System to build a pipeline of product candidates with commercial value
3. 17If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue which could materially adversely affect our business, financial condition and results of operations
4. 18maintaining a continued acceptable safety profile of our products following approval
5. 19third parties being unwilling or unable to satisfy their contractual obligations to us
6. 20The COVID-19 pandemic and government responses created disruptions in global supply chains, resulted in significant travel and work restrictions in many regions and caused a strain on healthcare resources, and have continued to adversely impact many industries
7. 21If we experience delays or difficulties in the enrollment and/or retention of participants in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented
8. 22proximity and availability of clinical trial sites for prospective participants
9. 23The market opportunities for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate
10. 24We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
11. 25collaborations, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do
12. 26Our competitors will also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and participant registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs
13. 27Interim, “top-line,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more participants data become available and are subject to audit and verification procedures that could result in material changes in the final data
14. 28Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, and others in the medical community
15. 29If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, or others in the medical community, we will not be able to generate significant revenue
16. 30Even if any products we develop achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete
17. 31If product liability lawsuits are brought against us, we may incur substantial liabilities, which may not be sufficiently covered by insurance, and may be required to limit commercialization of our product candidates
18. 32a decline in our share price
19. 33We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators

Risks Related to Regulatory Process and Other Legal Compliance Matters

1. 34the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
2. 35Accelerated approval by the FDA, even if granted for our current or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive regulatory approval
3. 36We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process
4. 37Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
5. 38injunctions or the imposition of civil or criminal penalties. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
6. 39Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations
7. 40the availability of capital
8. 41The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
9. 42Our employees, independent contractors, consultants, principal investigators, CROs, suppliers, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
10. 43Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties
11. 44customers, vendors, third-party payors or other related third parties to comply with such obligations could harm our reputation, subject us to significant fines and liability, or otherwise adversely affect our business
12. 45Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing
13. 46Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates

Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business

1. 47We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
2. 48In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth
3. 49improving our operational, financial and management controls, reporting systems and procedures
4. 50Business disruptions could materially adversely affect our future revenue and financial condition and increase our costs and expenses
5. 51Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited
6. 52Changes in tax law may adversely affect us or our investors

Risks Related to Reliance on Third Parties

1. 53our contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well as natural or man-made disasters; and
2. 54We currently, and may in the future, depend on single-source suppliers for some of the ingredients, components and materials used in, and the manufacturing processes required to develop, our product candidates
3. 55If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages
4. 56We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangements
5. 57collaborators may own or co-own intellectual property covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property
6. 58If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks
7. 59our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs

Risks Related to Intellectual Property

1. 60If any of our patents are found to be invalid or unenforceable, or if we are otherwise unable to adequately protect our rights, it could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates
2. 61Our success depends in part on our ability to protect our intellectual property rights. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to protect our intellectual property rights throughout the world
3. 62Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements
4. 63Any issued patents we may own covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO
5. 64We may become involved in lawsuits or litigation at the USPTO to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful
6. 65by our patents and patent applications or those of our future licensors is threatened, it could dissuade other companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business
7. 66Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
8. 67preclinical data and launch their product earlier than might otherwise be expected, and our competitive position, business, financial condition, results of operations and prospects could be materially adversely affected
9. 68Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our technology, products and product candidates
10. 69We may be subject to claims challenging the inventorship of our patents and other intellectual property
11. 70If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
12. 71Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline
13. 72We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors or their former employers
14. 73If we fail to comply with our obligations in any future agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with any licensors, we could lose license rights that are important to our business
15. 74the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners
16. 75Intellectual property rights do not necessarily address all potential threats

Risks Related to Our Common Stock

1. 76The price of our stock has been and is likely to continue to be volatile, and you may not be able to resell shares of our common stock at or above the price you paid
2. 77The realization of any of the above risks or any of a broad range of other risks, including those described in this “Risk Factors” section, could have a dramatic and adverse impact on the market price of our common stock
3. 78Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
4. 79A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly
5. 80Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, would result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
6. 81Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our securities
7. 82Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval
8. 83We do not intend to pay dividends on our capital stock, so any returns will be limited to the value of our stock
9. 84Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock
10. 85require a super-majority vote of stockholders to amend some provisions described above
11. 86Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law
12. 87we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents
13. 88We may be subject to securities litigation, which is expensive and could divert management attention
14. 89Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance
15. 90royalties, which may become an important source of our revenue. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next
16. 91the changing and volatile global economic and political environment
17. 92We will continue to incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives
18. 93Failure to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies
19. 94Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
20. 95Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations
21. 96We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors
22. 97exemptions from the requirements of holding non-binding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved
23. 98Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations
24. 99Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price
25. 100If our security measures are compromised, or the security, confidentiality, integrity, or availability of our information technology, software, services, communications or data is compromised, limited or fails, this could result in a material adverse impact
26. 101If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
27. 102If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline
28. 103Our business could be negatively impacted by corporate citizenship and environmental, social and corporate governance matters and/or our reporting of such matters
29. 104Geopolitical events and conditions could adversely affect our business, financial condition and operating results
30. 105The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business
31. 106Environmental, social and governance matters may impact our business and reputation